SL 401

Drug Profile

SL 401

Alternative Names: DT(388)IL3; DT388 IL3; DTIL3; SL-401

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Texas A&M University
  • Developer Stemline Therapeutics
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Dendritic cell inhibitors; Interleukin-3-receptor-alpha-subunit-antagonists; Peptide elongation factor 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I/II Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders
  • Preclinical Haematological malignancies; Hairy cell leukaemia
  • No development reported Chronic myeloid leukaemia; Lymphoma

Most Recent Events

  • 16 Nov 2017 Stemline Therapeutics completes enrolment in its phase II trial for Acute myeloid leukaemia (blastic plasmacytoid dendritic cell neoplasm) (First-line therapy, Second-line therapy or greater) in USA
  • 31 Oct 2017 Pooled top-line adverse events data from clinical trials in Acute myeloid leukaemia (blastic plasmacytoid dendritic cell neoplasm), Myeloproliferative neoplasms and Multiple myeloma released by Stemline Therapeutics
  • 31 Oct 2017 Top-line efficacy data from a phase III trial in Acute myeloid leukaemia (blastic plasmacytoid dendritic cell neoplasm) released by Stemline Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top